(IDYA) IDEAYA Biosciences, Inc. Business Model Canvas Research

IDEAYA Biosciences, Inc. works with the University of Manchester as a joint research partner in the PARG program, adding academic biology and translational science to stress-test target validity early. That extra depth helps cut discovery risk and sharpen the evidence base before bigger R&D spend.

• Joint PARG research support
• Stronger target validation
• Lower early discovery risk

IDEAYA Biosciences, Inc. depends on molecular diagnostics labs and oncology trial sites to find patients with MTAP deletions, GNAQ or GNA11 mutations, BRCA or HRD alterations, and MSI-H status. These partners make genetically defined enrollment possible and support faster screening in rare biomarker-linked cancer groups.

• Match patients by tumor genetics
• Use central biomarker testing
• Run trials at oncology sites
• Enable rare-subgroup enrollment

IDEAYA Biosciences advances early-stage pipeline work on PARG, Pol Theta, and WRN inhibitor programs, with research aimed at biomarker-defined cancers such as BRCA or HRD and MSI-H tumors. The key activities are medicinal chemistry, biology, and translational studies that turn target biology into clinical candidates.

• PARG, Pol Theta, WRN programs
• BRCA, HRD, and MSI-H focus
• Medicinal chemistry and translational work

IDEAYA Biosciences runs collaboration and trial ops by managing research alliances, clinical partners, and drug supply for partnered studies. In 2025, this supported a pipeline with multiple clinical-stage programs, including darovasertib and IDE397, and helped push assets into proof-of-concept readouts.

• Coordinates partner trials and supply
• Tracks proof-of-concept milestones
• Supports faster data readouts

IDEAYA Biosciences, Inc. uses deep biomarker and translational expertise to pick patients and shape trial design in molecularly selected oncology. Its core biology work spans 5 areas: MTAP, GNAQ, GNA11, BRCA, HRD, and MSI-H, which helps tighten enrichment and raise signal quality in small, targeted studies.

• 5 biomarker biology areas
• Patient stratification focus
• Trial design de-risking

IDEAYA Biosciences, Inc.’s research network links academic labs and pharma partners, widening target discovery and validation. Its 2025 pipeline still centers on proprietary inhibitors and target biology, and those IP rights are key to protecting programs and improving deal value.

• Academic and pharma ties broaden discovery
• Proprietary inhibitor and target IP protects pipeline
• IP strength supports partnering leverage

IDEAYA Biosciences focuses on biologically defined hard-to-treat cancers, including MTAP-deleted, GNAQ or GNA11 mutant, BRCA or HRD, and MSI-H tumors. These settings have high unmet need: MTAP deletion appears in about 10%-15% of solid tumors, while MSI-H tumors are roughly 4%-5% of all cancers.

• Targets rare, biomarker-driven cancers
• Covers multiple high-need oncology niches
• Built for precision medicine use

IDEAYA Biosciences, Inc. pairs internal discovery with 4 external partners—Pfizer, GSK, Cancer Research UK, and the University of Manchester—to broaden science and speed development. This partner-enabled model helps spread technical risk, add trial and research capacity, and keep more programs moving without building every capability in-house.

• 4 named external collaborators
• Internal discovery plus partner support
• De-risks science and expands capacity

IDEAYA’s patient ties are mediated by molecular testing and treating oncologists, so the funnel is narrow and trial-like. Eligibility is driven by biomarkers such as MTAP deletion, seen in about 10% to 15% of solid tumors, and GNAQ/GNA11 mutations, which drive most uveal melanoma.

• Testing-first, physician-led access
• Small, biomarker-defined patient pools
• High trial dependence, low broad reach

IDEAYA Biosciences, Inc. keeps active ties with regulators, key opinion leaders, and medical groups to shape trial design and evidence plans. This matters for a pipeline with multiple clinical programs, because early feedback can tighten endpoints, reduce protocol risk, and support future approvals.

• Regulator contact guides trial design
• KOL input strengthens evidence generation
• Medical ties help future approvals

IDEAYA Biosciences, Inc. uses oncology conferences and peer-reviewed publications to share clinical and biomarker data, which is vital in a pre-commercial model with FY2025 product revenue of $0. This channel helps build trust with investigators, partners, and investors as the company advances programs like darovasertib and IDE397.

• Key proof point: clinical data

• Builds credibility fast

• Supports partner talks

IDEAYA uses earnings releases, corporate presentations, and investor events to keep financing and partnering visibility high. For a public precision oncology company, these channels matter because they shape capital access, deal talks, and market trust.

• Supports financing visibility
• Supports partnering visibility
• Signals clinical progress fast

IDEAYA Biosciences, Inc. targets MSI-H cancer patients with WRN inhibitor programs because these tumors have high microsatellite instability and weak DNA repair, creating a distinct biomarker-led group. MSI-H occurs in about 3% to 5% of solid tumors, so the addressable pool is small but clinically clear.

• Biomarker-led segment
• WRN dependency in MSI-H tumors
• Small, high-need patient pool

Pfizer, GSK, academic institutions, and cancer research groups are key business customers for IDEAYA Biosciences, because they buy discovery assets, co-fund development, and help move targets into human data. This matters because IDEAYA is still pre-commercial, with 2025 revenue driven mainly by collaboration and license income, while pipeline partners help carry R&D risk.

• Partners pay for discovery and translational science
• Shared development reduces cash burn
• Pre-commercial model makes alliances critical

As a public Company, IDEAYA Biosciences, Inc. funds corporate overhead in general and administrative costs, including leadership, finance, legal, HR, and investor relations; in FY2025, this spend sat alongside total operating costs of roughly "latest filing required for exact figure" and supports governance plus capital markets access. These costs are usually smaller than R&D, but they rise with headcount, compliance, and financing activity.

• Leadership and board support
• Finance, legal, and HR
• Investor relations and filings
• Governance and market access

IDEAYA Biosciences, Inc. uses a partner-led model, so collaboration and licensing costs come from shared R&D funding, milestone payments, and IP control. In FY2025, these external contracts kept spend tied to program progress and added fixed legal and research obligations.

• Shared funding
• Milestone commitments
• IP management costs
• External research contracts

IDEAYA Biosciences, Inc. could earn future royalties only if partnered programs reach commercialization, with payments tied to product sales. As of fiscal 2025, the Company reported no royalty revenue, so this remains a contingent back-end biotech stream rather than current cash flow.

• Sales-linked royalties
• No royalty revenue in FY2025
• Only if partners commercialize

IDEAYA Biosciences, Inc. had no product revenue in its latest reported period, so future product sales are still a pipeline option, not a current stream. If an oncology drug wins approval, sales could come direct or through partners, but revenue will depend on FDA success, launch timing, and payer access.

• Current product sales: $0
• Revenue starts only after approval
• Partners may handle commercialization